巨子 ICON - 財經股票資訊及專家分析
快訊
資訊
    虛擬市場
    搜尋 股票/指數/編號

    快訊

    資訊

    Synthetic Biologics

    SYN
    1.530
    0.020
    1.29%
    最少15分鐘延遲,股票資訊由第三方資訊供應商提供
    ・Synthetic Biologics - 延遲價格・最後更新於 18/08 7:48
    最高位
    1.530
    最低位
    1.530
    開市價
    --
    前收市價
    1.550
    成交量(千)
    0.01
    成交額(百萬)
    0.00
    買入
    1.550
    賣出
    1.580
    每手股數
    --
    市值(百萬)
    24.24
    市盈率
    --
    息率
    --
    差價
    --
    52週高低
    5.575 - 1.350
    所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

    企業資料

    公司名稱
    Synthetic Biologics
    證券代碼
    SYN.US
    所屬板塊
    Biotechnology
    公司業務
    Synthetic Biologics is a late-stage biotechnology company focused on developing gut microbiome therapeutics. Its portfolio includes SYN-010, which is intended to treat the underlying causes of irritable bowel syndrome with constipation; and SYN-004 (ribaxamase), which aims to defend the gut microbiome from the effects of regularly used intravenous drugs for the prevention of C. difficile infection, antibiotic-associated diarrhea, and the emergence of antibiotic-resistant organisms. The company is also developing monoclonal antibody therapies for the treatment of pertussis and novel discovery stage biotherapeutics for the treatment of phenylketonuria.
    發行量
    158437841
    公司總部
    9605 Medical Center Drive, Suite 270
    公司網址
    https://www.syntheticbiologics.com
    公司電郵
    info@syntheticbiologics.com
    公司電話
    +1 301 417-4364
    暫無內容

    關於

    Synthetic Biologics(SYN.US)所屬的行業板塊為Biotechnology。
    Synthetic Biologics is a late-stage biotechnology company focused on developing gut microbiome therapeutics. Its portfolio includes SYN-010, which is intended to treat the underlying causes of irritable bowel syndrome with constipation; and SYN-004 (ribaxamase), which aims to defend the gut microbiome from the effects of regularly used intravenous drugs for the prevention of C. difficile infection, antibiotic-associated diarrhea, and the emergence of antibiotic-resistant organisms. The company is also developing monoclonal antibody therapies for the treatment of pertussis and novel discovery stage biotherapeutics for the treatment of phenylketonuria.
    詳細公司背景可參考: https://www.syntheticbiologics.com